Bajaj Healthcare Limited's Board of Directors convened on May 8, 2026, and approved the audited standalone financial results for the quarter and financial year ended March 31, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. For Q4 FY26, the company reported a net loss of ₹194M against a net profit of ₹112M in the same quarter last year, while quarterly revenue stood at ₹1.53B compared to ₹1.54B in Q4 FY25. The board also recommended a final dividend and made key auditor appointments for the financial year 2026-27. The statutory audit was conducted by Walker Chandiok & Co LLP, Chartered Accountants, who issued an unmodified opinion on the standalone financial results.

Financial Performance Overview

Bajaj Healthcare reported revenue from operations of ₹61,103.14 lakhs for FY26, compared to ₹54,260.24 lakhs in FY25. Total income for the year stood at ₹61,816.53 lakhs against ₹56,200.68 lakhs in the previous year. However, a significant exceptional item of ₹3,324.66 lakhs — arising from the reversal of income recognised in an earlier year related to a Technical Know-how transfer arrangement impacted by regional instability in the Middle East — weighed on the quarterly and full-year profitability. The following table summarises the key financial metrics:

Earnings Per Share

The earnings per share figures reflect the impact of the exceptional item during Q4 FY26. The EPS details are as follows:

Balance Sheet Highlights

As at March 31, 2026, total assets stood at ₹92,321.72 lakhs compared to ₹83,304.62 lakhs in the previous year. Total equity improved to ₹53,300.23 lakhs from ₹46,616.42 lakhs. Key balance sheet items are presented below:

Cash Flow Summary

Net cash flow from operating activities improved significantly to ₹5,808.13 lakhs from ₹2,162.05 lakhs in the previous year. Cash and cash equivalents at the end of the period stood at ₹3,723.54 lakhs compared to ₹260.38 lakhs at the start of the year.

Dividend and Corporate Actions

The board recommended a final dividend at the rate of 30% of the face value of ₹5 per share, amounting to ₹1.50 per equity share for FY2025-26, subject to shareholder approval at the ensuing Annual General Meeting. Additionally, the board approved the allotment of 20,79,409 fully paid-up equity shares at ₹338 per share (including a premium of ₹333) pursuant to the conversion of warrants, as part of a preferential issue approved at the Extra-Ordinary General Meeting held on August 7, 2024. The utilisation of funds raised through the preferential issue is detailed below:

Auditor Appointments and Discontinued Operations

The board appointed M/s. JCR & Co. LLP, Chartered Accountants, as Internal Auditors for FY2026-27 and re-appointed M/s. V.J. Talati & Co., Cost Accountants, as Cost Auditors for FY2026-27. Regarding discontinued operations, one unit situated at plot no. L-9/3, MIDC Tarapur was sold during Q4 FY26. The loss after tax from discontinued operations for FY26 stood at ₹554.43 lakhs compared to ₹343.33 lakhs in FY25. Separately, the company acquired Genrx Pharmaceuticals Private Limited (in Liquidation) on a going concern basis for a total consideration of ₹1,085 lakhs; the matter is pending with the NCLT as of March 31, 2026, and Genrx has not been consolidated as a subsidiary pending requisite approvals. The board meeting commenced at 5:15 p.m. and concluded at 6:30 p.m. on May 8, 2026, with the official communication signed by Monica Tanwar, Company Secretary and Compliance Officer.

Bajaj Healthcare Limited has received listing approvals from the National Stock Exchange of India Limited (NSE) and BSE Limited for 20,79,409 equity shares of face value ₹5/- each. The approvals, communicated on May 06, 2026, pertain to shares allotted pursuant to the exercise of options for the conversion of convertible warrants into equity shares on a preferential basis. The development was disclosed by the company in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was signed by Monica Tanwar, Company Secretary and Compliance Officer of Bajaj Healthcare Limited, on May 07, 2026.

Key Details of the Listing Approval

The following table summarises the key parameters of the approved listing:

Exchange Approvals and Conditions

NSE granted in-principle approval for the listing of the 20,79,409 equity shares, subject to confirmation from depositories NSDL and CDSL regarding the credit of beneficiaries' accounts. BSE similarly granted listing approval and noted that trading approval will be issued only after the company fulfils specific conditions.

The conditions stipulated by BSE for trading approval include:

• Submission of listing approval from NSE (if applicable)
• Confirmation letters from NSDL/CDSL confirming credit of the shares to respective beneficiary accounts and admission to the depository system
• Confirmation letters from NSDL/CDSL regarding lock-in of pre-preferential holding (if applicable)

Regulatory Compliance Requirements

BSE further directed Bajaj Healthcare to ensure compliance with Regulation 167 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations. The exchange also noted that, as per Schedule XIX of the ICDR Regulations and SEBI circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023, the company is required to make an application for trading approval to the stock exchanges within seven working days from the date of grant of listing approval. Non-compliance with this requirement will attract fines as specified in the aforementioned SEBI circular.

Additionally, BSE indicated that in the event of a change exceeding two per cent of the total paid-up share capital, the company shall file the shareholding pattern in XBRL mode as required under Regulation 31(1)(c) of the SEBI LODR Regulations, 2015.